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In order to evaluate the effect ofintrathecal gentamicin on gram-negative bacillary meningitis, twenty-eight
patients were treated with intralumbar or intraventricular gentamicin in combination with systemic gentami-
cin and with otherantibiotics. Sterile cerebrospinal fluid was achieved in 21/22 (95%) episodes ofdocumented
gram-negative bacillary meningitis in patients who received more than one day of therapy. Seventy-seven
percent of these patients survived their infection. The mean cerebrospinal fluid gentamicin level measured 24
hours after intrathecal administration was 5.9 ug/ml following intralumbar administration and 11.1 ug/ml
following intraventricular administration. Toxic side effects due to intrathecal administration ofgentamicin
were not noted. These findings suggest that both intralumbar and intraventricular administration ofgentami-
cin are safe and efficacious in the treatment of gram-negative bacillary meningitis.
Infection of the central nervous system with gram-negative enteric bacteria is a
significant problem among neonatal and neurosurgical patients. We have previously
reviewed the clinical characteristics of these patients [1]. Depressed host defenses,
multiple surgical procedures, foreign bodies and pathogenicity of infecting bacteria
all contribute to the low survival rate associated with these infections. Early therapy
with antibiotics that achieve adequate cerebrospinal fluid levels would appear to be
necessary to minimize neurologic damage and improve survival.
Penetration ofaminoglycoside antibiotics across the blood-brain barrier is variable
and little correlation between serum and cerebrospinal fluid concentrations has been
observed [2-5]. Animal studies indicate that low levels ofgentamicin in cerebrospinal
fluid are associated with considerable neurologic toxicity [6] whereas human case
reports have suggested that intrathecal injection of gentamicin is relatively safe
[7-21]. However, these studies report a wide range ofcerebrospinal fluid concentra-
tions among patients who receive equivalent doses ofintrathecal gentamicin (4 mg in
adults and 1 mg in infants). Since clinical experience with intrathecal gentamicin is
still quite limited, the efficacy, toxicity and appropriate dosage schedules remains
unclear. Our experience with intrathecal gentamicin was begun in 1970 as a prospec-
tive, non-randomized investigation in an attempt to determine the efficacy and
toxicity ofthis drug in patients with gram-negative bacillary meningitis. The present
report describes our observations in twenty-eight patients treated with intrathecal
gentamicin in combination with systemic gentamicin and with other antibiotics, and
represents the largest single series of patients observed in one medical center.
METHODS
Patient Selection
Patients were included in the study if their clinical course and cerebrospinal fluid
analysis were consistent with acute bacterial meningitis which was either proved or
suspected to be caused by gram-negative bacilli; ifthey were seen in consultation by
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one of us (RJM or VTA) at the onset oftheir illness; and ifthey ortheirfamilies gave
informed consent to receive the investigational drug. Twenty-eight patients (sixteen
adults, one child, and eleven infants) with suspected gram-negative bacillary meningi-
tis were treated with intrathecal and systemic gentamicin in combination with other
systemic antibiotics (Table 1). One patient (Case 4) was treated for two separate
infections. A bacteriologic diagnosis was confirmed by the isolation ofgram-negative
bacilli from the cerebrospinal fluid during twenty-three separate episodes ofmeningi-
tis which occurred in twenty-two patients. Gram-negative bacilli were seen on the
stained cerebrospinal fluid smear of the remaining six patients, although cultures
were sterile in four, and yielded Staphylococcus epidermidis in one and an enterococ-
cus in the other patient.
Therapy
Gentamicin sulfate in saline (2 mg per cc) (investigational drug, Schering Corpora-
tion, Newark, New Jersey), was administered either intrathecally by barbotage or
intraventricularly by a Richham or Ommaya reservoir. The decision to administer
gentamicin intraventricularly was determined by the presence of a Richham or
Ommaya reservoir which had been inserted previously because of the patients
underlying disease, e.g., hydrocephalus. In the absence of a reservoir, intrathecal
gentamicin was given by barbotage into the intralumbar subarachnoid space. In-
trathecal gentamicin in a dose of 4 mg was administered to thirteen adults at intervals
of 24 hours for two to fifteen successive days. Two adults received 2 mg/day for seven
and ten successive days respectively and one adult received 3 mg/day for nine
successive days. The eleven infants and one child received 1 or 2 mg at 24 hour
intervals for one to twenty-three successive days. Gentamicin sulfate was also admin-
istered intravenously or intramuscularly in a dose of 3-5 mg/kg per day. Other
antibiotics administered concurrently are listed in Table 1. In an attempt to evaluate
the effectiveness of intrathecal and intraventricular gentamicin in the treatment of
documented gram-negative bacillary meningitis in a non-randomized way, we com-
pared the survival rates of patients treated in the present series, with survival rates of
other patients with documented gram-negative bacillary meningitis who were seen in
this medical center during the same time period, but who did not receive intrathecal
or intraventricular gentamicin, although most were treated with either systemic
gentamicin alone or in combination with other antibiotics [1].
Aminoglycoside Analysis
Gentamicin serum and cerebrospinal fluid levels were measured by a bioassay
method previously reported [11]. The test organism, Bacillus globigii, was grown in
30 ml ofbrain-heart-infusion broth for 6 hours at 370 C. Then 3 ml ofthis culture was
added to 36 ml ofmodified Triptocase soy agar. Thirty-six milliliters was then poured
into petri dishes and allowed to solidify. One milliliter of penicillinase was added to
this mixture prior to cooling in all patients who were also receiving a penicillin
antibiotic. Samples obtained from patients who were receiving either oxacillin or a
cephalosporin were tested against Enterobacter aerogenes rather than Bacillusglobi-
gii in the bioassay. This strain of Enterobacter aerogenes is sensitive only to aminog-
lycoside antibiotics. After the medium was solidified, it was cooled at 50C for fifteen
minutes. Wells were produced with a 4 mm diameter bore and filled in duplicate with
gentamicin standard samples and with the patient's serum orcerebrospinal fluid. The
plates were then incubated overnight at 370C. The diameter of the zone ofinhibition
for the gentamicin standards and the unknown body fluid sample was measured with
a millimeter ruler. Gentamicin concentrations were calculated by regression analysis.
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RESULTS
Twenty-eight patients (eleven infants, one child and sixteen adults) received in-
trathecal or intraventricular gentamicin (Table 1). There were twenty-three episodes
ofgram-negative bacillary meningitis, which occurred in twenty-two patients, one of
whom was treated for two separate infections. Two additional patients had gram-
positive coccal meningitis, and no etiologic agent could be recovered from the
cerebrospinal fluid cultures of four others. Gentamicin was administered intraventri-
cularly to nine infants with documented meningitis who had Rickham or Ommaya
reservoirs in place at the onset of their infection (Table 1). Six of these nine infants
survived and were cured of their meningitis; two infants died, one of whom (patient
#5) also received intralumbar gentamicin in a dose of 2 mg/day concomitantly with
intraventricular gentamicin; and one infant experienced a relapse of his E. coli
meningitis three days after completing a fourteen day course of intraventricular
gentamicin (Table 2). Cerebrospinal fluid concentrations of gentamicin were ob-
tained in seven of these nine infants 24 hours (± 2 hours) after daily intraventricular
installation of I to 2 mg, and ranged from 3 to 30.5 ug/ml with a mean of 11.1 ug/ml
(Fig. 1). Intralumbar gentamicin was administered to twenty patients, sixteen adults,
one child, and three infants (Table 1). Sixteen of these twenty patients had docu-
mented infections, fifteen ofwhich were caused by gram-negative bacilli, and one was
caused by an enterococcus. Twelve ofthe sixteen patients with documented meningi-
tis who received intralumbar gentamicin, were cured of their infection and four
patients died. Four additional patients received intralumbar gentamicin for suspected
gram-negative meningitis but their cerebrospinal fluid cultures were sterile. Two of
these patients survived and two died (Tables 1 and 2). Cerebrospinal fluid concentra-
tions of gentamicin obtained 24 hours (± 2 hours) after daily intralumbar administra-
tion ranged from 1 ug/ml to 20 ug/ml (mean 5.9 ug/ml) in these patients (Fig. 1).
Concentrations ofcerebrospinal fluid gentamicin were significantly higherduring the
first six days of therapy when compared to the 7th through the 13th days oftherapy
(p < .001) (mean for days 1-6 = 9.168 ug/ml, S.E.±1.36, mean for days 7-13 = 3.149
ug/ml,S.E. ± 0.65). In no patient was there an indication ofgentamicin accumulation
in the cerebrospinal fluid after successive doses. In order to determine whether there
were changes in opening pressure ofthe lumbar punctures over the course oftherapy
which were related to the decreasing cerebrospinal fluid gentamicin levels, opening
pressures were plotted against time in six patients and no trend in these pressures
over the course of therapy was observed. Of thirty-eight lumbar cerebrospinal fluid
samples obtained in nine patients during the first seven days of therapy (24 hours
after the intralumbar administered dose) the gentamicin level was greater than 2
ug/ml in thirty-one samples, and greater than 3 ug/ml in twenty-five samples from all
patients studied. Specifically, most of the cerebrospinal fluid samples from every
patient contained concentrations of gentamicin in excess of 3 ug/ml 24 hours after
intralumbar instillation. In several instances, cerebrospinal fluid and serum samples
were obtained from the same patient at the same time. Cerebrospinal fluid and serum
were obtained 24 hours after the last intrathecal or intraventricular dose and 4-6
hours after the previous systemic dose. Regression analysis of simultaneous cerebro-
spinal fluid and serum gentamicin levels revealed no significant correlation (correla-
tion coefficient r = 0.44).
Cerebrospinal fluid was cultured daily during intrathecal therapy. The median time
that sterile cerebrospinal fluid was achieved was 72-96 hours after institution of
therapy (Fig. 2). However, several patients that survived required more than one
week of therapy before eradication of their meningitis.
Blood urea nitrogen and serum creatinine remained normal in twenty-eight pa-
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TABLE 2
Clinical Comments
Patient #2 -Pseudomonas aeruginosa cultured from CSF after 5 days of treatment. Antibiotics discontinued at that
time because of irreversible neurologic damage. Patient died 15 days later, no meningitis at postmortem.
Patient #3 -Died 12 hours after therapy was begun.
Patient #4 -Proteus mirabilis infection cured after 5 days of intrathecal therapy. Reinfected 5 days later with E. coli
while receiving intramuscular gentamicin. Cured again with intraventricular therapy.
Patient #5 -Antibiotics discontinued after 5 days because of irreversible neurological damage. CSF remained sterile to
death one week later.
Patient #6 -Relapse day 17, 3 days after discontinuance of antibiotics. Cured with chloramphenicol retreatment.
Patient #9 -Mixed infection (Bacteroidesfragilis, Klebsiella, Proteus mirabilis, enterococcus, E. coli). Gram-negative
bacillary infection cured in 3 days, Bacteroides persisted 20 days. Patient returned 5 months later with
Bacteroides osteomyelitis of skull and eventually cured.
Patient #16-Cerebrospinal fluid sterile after 3 days of therapy, but patient died of irreversible neurological damage.
Active inflammation or possible infection noted at postmortem.
Patient #19-Klebsiella noted to be resistant to gentamicin which was discontinued after 4 days. Treated with polymycin
B intrathecally. Died after 24 days of infection. Multiple brain abscesses noted at postmortem.
Patient #22-Cerebrospinal fluid sterile after 24 hours. Patient died of overwhelming gram-negative sepsis.
Patient #23-Reveived ampicillin and kanamycin prior to first lumbar puncture. Gram-negative bacillary meningitis
suspected clinically.
Patient #25-Widespread cerebritis and purulent meningoventriculitis from septic embolism from mitral valve acute
endocarditis noted at postmortem.
Patient #26-Brain abscess suspected clinically. CSF sterile. Cerebellar abscess (culture sterile) found at postmortem.
Patient #27-Post-myelogram meningitis suspected, but CSF sterile. Responded clinically to antibiotics.
Patient #28-Documented enterococcal meningitis. Synergy between ampicillin and gentamicin was not observed.
Therefore, gentamicin was discontinued after 48 hours.
tients treated with intrathecal or intraventricular gentamicin. No acute toxicity was
noted following the instillation of gentamicin. No transient hypotension or respira-
tory distress was observed. Pre-treatment auditory and vestibular function was not
evaluated because of the critically ill status of the patients prior to therapy. Eight
patients, followed four months to three years after intrathecal therapy had no
evidence of vestibular or auditory dysfunction. One child was noted to have a broad
gait two years after therapy. However, since the meningitis had occurred following
surgical exploration of the posterior fossa and partial resection of the cerebellum,
vestibular damage due to gentamicin was difficult to assess. Another infant was
severely retarded with cortical blindness and absence of control oflowerextremities,
bladder, and bowel three years after hospitalization. However, since she had had
multiple surgical procedures for meningomyelocele repair as well as ventricular
shunts, the possibility of gentamicin toxicity could not be evaluated.
Meningitis was documented in twenty-four oftwenty-eight patients treated in this
study. One of these twenty-four patients had two separate documented episodes of
infection thereby permitting an evaluation of the efficacy of gentamicin, when
administered directly into the cerebrospinal fluid, in twenty-five separate episodes of
meningitis in twenty-four patients. Eighteen of these twenty-four patients with
documented meningitis, including the patient with two episodes of meningitis,
survived their infection, although one patient relapsed and was subsequently cured
with chloramphenicol. Furthermore, infection was eradicated prior to death in four
of the six patients who died from severe neurological damage. Therefore, sterile
cerebrospinal fluid was observed in twenty-one of twenty-four patients with docu-
mented meningitis. Survival rate in patients with documented infections, was notINTRATHECAL GENTAMICIN IN MENINGITIS
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FIG. 1. CSF gentamicin concentration 24 hours after intrathecal or intraventricular administration. Intrathecal
gentamicin was given in adaily dose of4mgfor adults and 1-2 mg for infants. Intraventricular gentamicin was only given
to infants and in a dose of 1-2 mg daily.
influenced in this series by the method ofgentamicin administration; i.e., intralumbar
by barbotage (twelve cures, four deaths) as compared to intraventricular (six cures,
one relapse, two deaths) p=>0.50), or by age, i.e., infants (seven cures, one
relapse, three deaths) as compared to adults (eleven cures, three deaths)
(p =>0.20). Furthermore, there was no significant difference in survival rates between
infants (six cures, one relapse, three deaths) and adults (ten cures, three deaths)
(p =>0.10), or method of gentamicin administration, intralumbar (eleven cures,
four deaths) as compared to intraventricular (five cures, one relapse, two deaths)
(p =>0.30) for those patients with documented gram-negative bacillary meningitis.
In the present series, all patients received systemic gentamicin in addition to
gentamicin administered directly into the cerebrospinal fluid either by intralumbar
barbotage or by intraventricular injection. Other systemic antibiotics were adminis-
tered concurrently to the twenty-two patients during twenty-three separate episodes
of documented gram-negative bacillary meningitis as follows: three patients received
no other therapy; seven received an antibiotic to which the infecting organism was
resistant; five received chloramphenicol; five received ampicillin; two received both
chloramphenicol and ampicillin; and one received carbenicillin (Table 1). The infect-
ing organism was eliminated from the cerebrospinal fluid in twenty-one of these
twenty-three episodes ofdocumented gram-negative bacillary meningitis. One patient
(Case 3) died within 12 hours of admission and received only one dose ofantibiotic
therapy. Therefore, intrathecal gentamicin was associated with elimination of the
infecting bacteria from the cerebrospinal fluid in 21/22 episodes (95%) of meningitis
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FIG. 2. Positive CSF cultures during intrathecal gentamicin therapy. Cultures were obtained daily.
in patients who received more than one day oftherapy. In the present series, seventy-
seven percent, 17/22 episodes, of patients survived their infection. The mortality rate
in the present study of 23%, in patients who have received intrathecal gentamicin for
documented gram-negative bacillary meningitis is the lowest that we have observed in
patients with this infection who were seen during the same time period at this medical
center [1]. Specifically, we have observed a mortality rate of 100% in five patients
with documented gram-negative bacillary meningitis who received no antibiotic
therapy for their infection, and a mortality rate of 50% in forty-six patients with
documented gram-negative bacillary meningitis who were treated with systemic
antibiotics, including amihoglycosides, but who did not receive intrathecal gentami-
cin [1]. These patients were comparable in age and underlying disease to the present
group of patients who received intrathecal therapy [1]. Although the differences in
mortality rates between those patients with documented gram-negative bacillary
meningitis who received systemic antibiotics without intrathecal gentamicin (23/46)
and those who received systemic antibiotics with intrathecal gentamicin (5/22) are
not statistically significant (X2 = 3.51, p = 0.05 - 0.10), the numbers of patients are
small and the results indicate a trend toward statistical significance.
DISCUSSION
Therapy of patients with central nervous system infection due to gram-negative
enteric bacteria remains an unsolved problem in the modern medical era. These
infections are of major concern among patients with depressed host defenses, follow-
ing neurosurgery and in the neonatal period [1,22]. Chloramphenicol is the only
antimicrobial agent currently available that offers both a wide spectrum of activity
against gram-negative organisms and excellent penetrance across the blood-brain
barrier. However, this agent is frequently not suitable for neonatal patients. Pene-
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trance ofcephalosporin and aminoglycoside antibiotics into the cerebrospinal fluid is
not adequate to treat meningitis [1,24]. The spectrum of antibacterial activity of
ampicillin is too narrow to treat many ofthese infections and there is little experience
with carbenicillin or trimethoprim-sulfamethoxazole. Since preliminary studies had
demonstrated that intrathecal gentamicin might be a safe and efficacious drugfor the
treatment of meningitis, the present clinical study was begun six years ago. Our
results indicate that the administration of 4 mg of gentamicin intrathecally usually
provides therapeutic levels of antibiotic for at least 24 hours. This treatment schedule
is well tolerated with no obvious major toxicity. The survival rate in the present series
of patients compares favorably to previous reports of patients with gram-negative
bacillary meningitis.
Following intralumbar administration of gentamicin, a peak level in excess of 50
ug/ml is achieved with a subsequent T 1/2 of about 51/2 to 6 hours [19,20]. In the
present study, the levels of gentamicin obtained in the cerebrospinal fluid 24 hours
after intrathecal antibiotic administration, in all patients studied, were greater than 2
ug/ml in 31/38 determinations and greater than 3 ug/ml in 25/38 determinations
tested during the first week of therapy. Our results are in contrast to those of Rahal
who noted levels of less than 3 ug/ml in two-thirds of the patients' samples studied
twenty hours after intrathecal gentamicin administration [19]. This difference may be
explained, in part, by differences in the method ofadministering intralumbar gentam-
icin, which in the present study, was given by barbotage. The great majority ofgram-
negative bacillary central nervous system infections are due to either E. coli or
Klebsiella [1]. These bacteria are usually sensitive to concentrations of gentamicin
below 2 ug/ml [23]. Therefore, we disagree with the 18 hour dosage schedule
previously recommended by others [19], and we continue to administer intrathecal
therapy every 24 hours. Our observations suggest that the trough gentamicin level is
in excess of the minimum bactericidal concentration in the majority of cases. Fur-
thermore, this regimen appears to provide acceptable clinical results and may also
decrease the risk ofdrug toxicity. Highly resistant organisms may, ofcourse, require
higher doses of gentamicin or more frequent intrathecal therapy.
We did observe higher mean cerebrospinal fluid gentamicin concentrations follow-
ing intraventricular as compared to intralumbar therapy. In addition, as noted by
Kaiser and McGee [20], intraventricular cerebrospinal fluid aminoglycoside levels
may be unsatisfactory despite therapeutic levels of drug in the lumbar cerebrospinal
fluid. Although this consideration is certainly valid, the importance and toxicity of
high intraventricular levels is unknown. In addition, it is very often not feasible to
initiate intraventricular therapy in acutely ill patients who do not have an indwelling
ventricular reservoir. Therefore, until further data are available, we would agree that
when available, intraventricular therapy is probably preferable to the intralumbar
route. However, our observations do not support the conclusion of others that
intralumbar therapy has no advantage over intravenous administration. In addition,
since delay in therapy significantly reduced prognosis of meningitis, intralumbar
administration should be initiated prior to surgery if a reservoir is to be placed.
Lower concentrations of cerebrospinal fluid gentamicin were noted during the
second week of therapy. One possible explanation for this observation may be to
decrease inflammation of the meninges associated with improved circulation and
drainage of cerebrospinal fluid. Cerebrospinal fluid gentamicin levels in the sub-
optimal therapeutic range during the second week of treatment do not appear to be
of major clinical significance since only one patient relapsed following intrathecal
gentamicin therapy.
Subtle neurologic toxicity due to intrathecal gentamicin could not be adequately
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assessed because many patients were critically ill, and because of the associated co-
morbid factors of neurosurgery and/or congenital central nervous system defects.
However, no vestibular or audio toxicity could be directly attributed to gentamicin.
Cerebrospinal fluid gentamicin levels were in excess of 10 ug per milliliter 24 hours
after installation in at least eight patients. Presumably the level is even higher
immediately following administration of the antibiotic. This apparent tolerance of
humans to high levels of cerebrospinal fluid gentamicin is in contrast to vestibular
dysfunction noted in cats with cerebrospinal fluid gentamicin concentrations that are
only 1% of serum levels [6].
Previous reviews of gram-negative bacillary meningitis indicate a survival rate
between 20-60% [1,22]. In the present study infection was eradicated in 95% of
episodes of gram-negative meningitis in patients who received more than one day of
therapy. Seventy-seven percent of these patients survived their infection. Although
the patients in the present study were not randomized and comparison with other
studies is difficult, the high survival rate of the present study suggests that intrathecal
gentamicin is an effective form of therapy. It should be noted that some individual
patients suffered irreparable neurologic damage despite the fact that central nervous
system infection was cured. Therefore, early diagnosis and treatment appears to be an
essential aspect of therapy. We currently recommend that intrathecal gentamicin in
combination with other broad spectrum antibiotics be instituted in cases ofsuspected
gram-negative bacillary meningitis in high risk patients such as neonatal, post-
surgical or immunosuppressed individuals. Since E. coliand Streptococcus pyogenes,
group B are the major cause of neonatal meningitis, we initiate therapy with ampicil-
lin, and intrathecal and intravenous gentamicin in these patients. Older children and
adults with gram-negative bacillary meningitis are initially treated with chloramphen-
icol, and intrathecal and intravenous gentamicin.
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